ADAMIS PHARMACEUTICALS CORPORATION

Dennis J. Carlo, Ph.D. - President & Chief Executive Officer

            Dr. Dennis J. Carlo has extensive biotech experience and is widely-regarded as one of the “Founding Fathers” of the biotech industry. He was one of the original “Test Tube Cowboys” of Hybritech Inc., where he served as Vice President of Research and Development and Therapeutic Manufacturing prior to its acquisition by Eli Lilly & Co. Soon after the sale to Lilly, Dr. Carlo, along with Dr. Jonas Salk of the Salk Institute, founded The Immune Response Corporation where he served as its President and Chief Executive Officer. In 1991, Ernst & Young named Dr. Carlo its Biotechnology Entrepreneur of the Year. Most recently, he served as president of Telos Pharmaceuticals, a privately-held biotechnology company.

            Dr. Carlo has a long history of leadership in the development of vaccines and biologics. Early in his career, as Director of developmental and basic cellular immunology and Director of bacterial vaccines and immunology at Merck & Co., he oversaw research and product development for PNEUMOVAX (14-valent polysaccharide vaccine), MENINGOVAX A, MENINGOVAX C, MENINGOVAX A-C, and H. influenzae type b, and also directed a multi-disciplinary task force whose goal was the development of novel adjuvants. At Hybritech, he put together a successful program to carry out research and development in the area of monoclonal antibody and cancer therapy. At the Immune Response Corporation, he established a program for an AIDS therapeutic vaccine and led the product development in successful clinical trials.

            Dr. Carlo has served on the Board of Directors and Advisory Boards for several public and private companies. Dr. Carlo has a Ph.D. in Immunology and Medical Microbiology from Ohio State University and is named on 23 patents and has authored over 225 articles and abstracts in the field of immunology.

Robert O. Hopkins - V.P. of Finance & Chief Financial Officer

 
           For four years, Mr. Hopkins was an Executive Vice President and the Chief Financial Officer of Chatham Capital Corp. In that position he managed financial operations for a corporation that held seven hospitals, an extensive life sciences operation and a number of semi-autonomous business units within its portfolio.

         Mr. Hopkins has substantial financial and operating experience outside of the medical services industry. He served as Chief Financial Officer of Veritel Corp, leading the turnaround of troubled biometric software company with heavy debt and difficulties raising capital. He has also served as Chief Operating Officer for Circle Trust Company for two years, during which time he was responsible for corporate reorganization after acquiring a troubled Trust Company.

         For two years, Rob was Senior Vice President for Finance for the Mariner Post-Acute Network, Atlanta, Georgia. In this position he was responsible for financial management of a division consisting of 12 long-term, acute care hospitals. Among his previous medical-related experience, he served as Assistant Administrator of Finance for Kindred Hospitals; President and Chief Executive Officer of Doctors Hospital of Hyde Park; and Vice President of Accounting for Cancer Treatment Centers of America.

         Mr. Hopkins has a Bachelor of Science in Finance from Indiana State University, and an M.B.A. from Lake Forest Graduate School of Management.

David J. Marguglio - V.P. of Business Development & Investor Relations

            Mr. David J. Marguglio has a broad knowledge of the corporate finance, private equity, and investment banking industry. For over 10 years, he has held positions of Vice President with Citigroup Global Markets, Smith Barney and Merrill Lynch. Prior to entering the financial industry, David founded and ran two different startup companies, the latter of which was eventually acquired by a Fortune 100 company.

            Mr. Marguglio began his professional career as a financial analyst and soon became engaged in preparing financial modeling and damage analysis utilized in corporate litigation. From 1993 to 1994, he served as financial counsel for the commercial litigation division of a national law firm. Mr. Marguglio is a licensed securities representative, securities agent, and investment advisor. He holds a degree in finance and business management from the Hankamer School of Business at Baylor University.

Thomas Moll, Ph.D. - V.P. of Research

            Dr. Thomas Moll has close to 20 years of experience in both academic and industrial preclinical research and development in the areas of inflammation, immunology and cancer biology. As part of his work, Dr. Moll has gained extensive experience in the generation, production and use of biologics, including protein/Fc chimeras, antibodies and gene therapeutics. After concluding his diploma studies in Biochemistry at the Biocenter, University of Basel, Switzerland, Dr. Moll received his doctorate degree in Genetics and Biochemistry “With Honors” from the University of Vienna, Austria. Subsequent to his work with Boehringer Ingelheim and Sandoz (now Novartis) in Vienna, Austria, Dr. Moll served as Assistant Professor at the UniversityMuenster, Germany, before joining Cardion, a privately held German biotech company. At Cardion, (then Cardiogene) Dr. Moll was initially in charge of the company’s preclinical cardiovascular gene therapy program, before taking over the responsibility for Cardion’s immunology programs as Vice President of Immunology. In this function he supervised the research and preclinical development of several protein/Fc fusion proteins, including CRB-15, an antagonist IL-15/Fc fusion protein. In 2003, Roche Pharmaceuticals licensed this protein for clinical development in various autoimmune disease indications. Before joining the Adamis management team, Dr. Moll was responsible for all research and development activities at Telos Pharmaceuticals. Dr. Moll serves as Editor of the Journal of Immune Based Therapies and has been a member of the European Society of Gene Therapy, the North American Vascular Biology Organization, the American Association of Immunologists, and the American Society of Transplantation. of

Maurizio Zanetti, M.D. - Chief Scientific Advisor

            Dr. Maurizio Zanetti, M.D. is a Professor in the Department of Medicine of the University of California, San Diego and a member of the Moores UCSD Cancer Center. He received a Bachelor of Arts in Classical Studies from Lyceum Marcantonio Flaminio of Vittorio Veneto, Treviso, Italy. In 1974, he received his M.D. degree “summa cum laude” from the University of Padova Medical School, Italy. In 1977, he passed the Board in Nephrology at the University of Padova Medical School. He trained in Immunology at the University of Paris VI in Paris, France, the University of Connecticut Health Sciences in Farmington, CT, and The Scripps Research Institute in La Jolla, CA.

            Dr. Zanetti is a member of the American Association of Immunologists, the American Society for Clinical Investigation, the Clinical Immunology Society, the Henry Kunkel society, the Robert A. Good society, the Societe’ Francaise d’Immunologie, and the Societa' Italiana di Immunologia. He served as Associate Editor for the Journal of Immunology and Cellular Immunology. He served as member on NIH Study Sections since 1998. Prior to that, he served as a member for the Immunology review panel of the American Cancer Society. He served as ad hoc reviewer for the National Science Foundation and the Human Frontier Science Program, as well as for numerous scientific journals including: Nature, Nature Medicine, Nature Biotechnology, The Proceedings of the National Academy of Sciences, The Journal of Immunology, Blood, Cancer Research, and Clinical Cancer Research.

            He has been an invited speaker at over 60 national and international conferences and symposia, has published more than 150 articles on peer reviewed journal and contributed numerous book chapters. He was Editor of “The Molecular Basis of Pathology”, the book series “The Antibodies” and served as guest Editor of “Cancer Immunotherapy” for Springer Seminars of Immunopathology.

 

ADAMIS LABORATORIES, INC.

Richard L. Aloi - President

            Mr. Aloi founded Aero Pharmaceuticals in 1997. He developed Aero into a distributor of allergen extracts and related products, and managed Aero’s transition to a specialty pharmaceutical provider. From 1979 to 1997, before founding Aero, Mr. Aloi was Director of Sales and Marketing at Center Laboratories (a division of E. Merck), a manufacturer of allergenic extracts and prescription respiratory products, including the market leading epinephrine auto-injector. At Center Laboratories, Mr. Aloi oversaw a 50-person marketing group which included over 35 field sales representatives. His earlier positions within Center Laboratories included Sales Representative, Regional Manager, and National Sales Manager. Mr. Aloi has served in leadership and advisory roles for industry groups, including the Allergen Product Manufacturers Association, the AmericanCollege of Allergy Asthma & Immunology, and the American Academy of Allergy Asthma & Immunology. Mr. Aloi earned his B.A. in Political Science from Boston College in 1976.

Richard B. Frost – Vice President, Business Development

            In February 1996, Mr. Frost became the Chairman of the Board of Directors and Chief Executive Officer of Frost Hanna Capital Group, Inc., a company formed to acquire an operating business. In August 1999, Frost Hanna Capital Group, Inc. consummated a business combination with Gaines Berland, Inc., which later merged with Ladenburg Thalmann Financial Group, Inc., a broker-dealer member firm of the New York Stock Exchange and the NASD. Previously, Mr. Frost was the Chief Executive Officer and Chairman of the Board of Directors of Frost-Hanna Mergers Group, Inc. (“Frost-Hanna Mergers”), a company also formed to acquire an operating business. Frost-Hanna Mergers later merged into Pan American World Airways, Inc. (“Pan Am”). Mr. Frost remained a member of the Pan Am Board of Directors until April 1997, when Pan Am merged with Carnival Airlines. In February 1998, Pan Am filed for Chapter 11 bankruptcy protection in the United States Bankruptcy Court. Mr. Frost earned a B.A. in Psychology from the University of Miami in 1970.

Thomas C. Parker - Vice President, Marketing and Sales

            Mr. Parker joined Aero Pharmaceuticals in March 2004. Prior to which, Mr. Parker was the co-founder and a partner of PharmaNova, LLC, and a drug development/drug delivery biotech company. From April 2000 to August 2002, Mr. Parker was the General Manager for Collateral Pharmaceuticals/Therapeutics, a gene therapeutics specialty company. From January 1996 to April 2000, Mr. Parker was the Senior Vice President of Marketing/ Sales and Business Development for Celltech Pharmaceuticals US. Mr. Parker has held senior management positions with Medeva Pharm US and Fisons Corporation. Mr. Parker has a B.S. degree from University of Tennessee/Pacific Western University and is a graduate of the medical marketing program at John Anderson Graduate School of Business at UCLA.